IBCSG 39-11 / BIG 4-11 (APHINITY)

  • A randomized multicenter, double-blind, placebo-controlled comparison of chemotherapy plus trastuzumab plus placebo versus chemotherapy plus trastuzumab plus pertuzumab as adjuvant therapy in patients with operable HER2-positive primary breast cancer.

    • Study Chairs
      Prof. Dr. med. Gunter von Minckwitz - Düsseldorf, Germany
      Jose Baselga, MD, PhD - Boston, MA
      José Bines, MD - Rio de Janeiro, Brazil

      IBCSG Study Chair
      Prof. Guy Jéruslem, Liège, Belgium

      Statisticians
      Ian Bradbury, PhD - Kincraig, Scotland

      Director of the Data Management Center
      Holly Shaw

      Monitoring
      ETOP IBCSG Partners Foundation
      Coordinating Center, Bern, Switzerland
      Phone: +41 31 511 94 00
      Fax: +41 31 511 94 01
      Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

      IBCSG Data Management
      Center / Frontier Science Foundation
      4033 Maple Road
      Amherst, New York 14226 USA
      Phone: +1 716 834 0900
      Fax: +1 716 833 3990
      Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

      Date of Activation:
      October 4, 2011

      Targeted Accrual:
      3806 patients

      Final Accrual
      4805 patients

      Date of closure
      August 31, 2013

    ETOP IBCSG Partners Foundation
    Effingerstrasse 33
    3008 Bern, Switzerland

    Contact
    Phone: +41 31 511 94 00
    E-mail: contact@etop.ibcsg.org

    Member Login